Hand hygiene promotion and the participation of infection control link nurses: An effective innovation to overcome campaign fatigue  by Ching, Patricia
Abstracts of the 7th International Congress of the Asia Pacific Society of Infection Control, Taipei, Taiwan, March 26-29, 2015 S7Standards includes Standard 3 “Preventing and Controlling Healthcare
Associated Infections”. The intent of Standard is to:
“Prevent patients from acquiring preventable healthcare associated infec-
tions and effectively manage infections when they occur by using evi-
dence-based strategies”.
The NSQHS Standards are being implemented in all public and private
hospitals and day procedure centres in Australia.KS 15
INFECTION CONTROL 2025
Andreas Voss. CWZ & RUMC, Nijmegen, The NetherlandsIn the talk the personal opinion of the
speaker with ragd to infection control and
its development over the next 10 years. The
talk will be centered around 6 main topics:
ʘ Basics are the new black
ʘ MDRO e are they all equal?
ʘ Regional efforts
ʘ Perceptions (Infection Control vs
Clinicians)
ʘ Less is more! (Guidelines)
ʘ Help e by design and by patientsThe content of the 6 basic principles on which Infection Control should focus
will be further explained. In addition other factors might be mentioned, such
as: infection control indicators, public reporting (2nd gen surveillance),
integration of MMB/ID/AMS/IC at regional levels, remote video assisted
behavior change (audits), nanotechnology for surfaces, virtual reality/
serious gaming. for HCWs training, robots/avatars for patients assist
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THE MANAGEMENT AND A NEW STRATEGY AGAINST CARBAPENEM-
RESISTANT ENTEROBACTERIACEAE INFECTION
Kazuhiro Tateda, MD, PhD. Department of Microbiology and Infectious
Diseases, Toho University School of Medicine, Tokyo 143-8540, JapanAppearance and spreading of antibiotic
resistant organisms are everywhere in the
world. In Japan, we have still problems of
MRSA in the hospital and also recent epide-
miological data demonstrated increase of
community-associated MRSA not only in
healthy individuals but hospital-admitted
patients. Not many, but we experienced
several outbreaks of multiple drug resitant
Pseudomonas aeruginosa and Acinetobacter
baumannii infections. Colistine is now a
topic of antibacterial to treat MDR organ-isms, which was created in Japan for the first time on 1950’. In historical
perspective, Japanese pharmaceutical companies have created interna-
tionally well accepted and widely used antibiotics, like cephazoline, levo-
floxacin, clarithromycin, tazobactam/piperacillin and meropenem. But
unfortunately, we are facing to a difficulty to produce newer generation
of antibacterials, even from those companies that produced golden stan-
dard compounds. In this talk, I would like to review several pipelines of
antibiotics which were evaluated in vitro, in vivo animal model and clin-
ical trial in some compounds. Some of them were reviewed in ICAAC
2014 in US, as promising agents in poster summary session. In addition, I
would like to show some experimental data of antibiotic therapeutic stra-
tegies, such as rationale of combination treatment (Break-point checker-
board plate) and inhibitors of metallo-beta-lactamase by zinc-chelating
agents.KS 17
CONTROLLING MULTI-DRUG RESISTANCE
Ian M. Gould. Royal Infirmary, Aberdeen, United KingdomThe question posed by the title is one of the critical
issues for health care at present, and surely for all
time unless some new ways to control bacteria can
be developed.
Resistance would not be an issue were it not for the
widespread use of antibiotics so, in the absence of
significant new antibiotic development, our efforts
must concentrate on reducing selection of resistance
and preventing its transmission.
Most experience, and success, has been gained
through our efforts to control hospital MRSA, and I
will discuss recent experience in the UK, USA andEurope to illustrate several basic principles that might be applied to the
control of most multi-resistant organisms.
For many years hospitals tried to control MRSA with “horizontal”
measures, that is generic precautions (often known as standard pre-
cautions) such as hand washing that it was envisaged would stop spread
of many pathogens. Clearly these failed to control MRSA, and as we
learnt more about its epidemiology, we were able to design specific
(vertical) precautions that specifically targeted the selection and spread
of MRSA.
Implementation of such measures in the UK in particular, has been
spectacularly successful in controlling MRSA. Universal admission screening
for MRSA, patient isolation and decolonization and the avoidance of key
antibiotics eg cephalosporins and quinolones have been particularly effec-
tive. Adjunctive measures such as improved hand hygiene and environ-
mental decontamination can also play a role.
The application of the same general principles to control of other MDR
organisms will likely be effective, if they are targeted to particular aspects
of the epidemiology of each organism.
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HAND HYGIENE PROMOTION AND THE PARTICIPATION OF INFECTION
CONTROL LINK NURSES: AN EFFECTIVE INNOVATION TO OVERCOME
CAMPAIGN FATIGUE
Patricia Ching, Principal Nurse. WHO Collaborating Centre on Infectious
Disease Epidemiology and Control, The University of Hong Kong, Hong Kong
Special Administrative RegionThe WHO has introduced a multimodal meth-
odology for the implementation of the hand
hygiene program. After a few years of promo-
tion and implementation, a common problem is
campaign fatigue when there is evidence that
promotional activities are being ignored and
hand hygiene compliance plateau at just 50%.
Three methods are often used to overcome this
including keep on expanding the campaign,
effective linkage to other healthcare programs,
and regular reinforcement.
An examples will be presented from the HongKong experience. (Seto et al AJIC 2013 (41):12: 128). Hand hygiene was
introduced in the 850-bed Hong Kong Baptist Hospital (HKBH) showing signif-
icant improvement in compliance in 2008 from 41% to 58% (p<0.01). Subse-
quently from 2008 to 2011, it persists below the 55% level in spite of active
promotional activities, indicating campaign fatigue. HKBH has 99 infection
control link nurses (ICLNs) and using focus groups, four key deficiencies
were identified and for each, a program was implemented to resolve
them. The four programs are as follows:
1. Help your doctor for excellence in Hand Hygiene: To reverse the low
compliance among doctors, accompanying nurses squirt alcohol for them
during ward rounds.
2. Competition for “Speaking Walls” posters: ICLNs help each ward to pro-
duce self-made posters because the present reminders were deemed inef-
fective. It is believed that self-designed posters will be better reminders.
S8 Abstracts of the 7th International Congress of the Asia Pacific Society of Infection Control, Taipei, Taiwan, March 26-29, 20153. Identifying locations for Point-of-care hand rubs: ICLNs reported that
there are strategic locations not mounted with rubs and identified 22
such locations.
4. HH education program and daily checklist for health care assistants
(HCAs): This is implemented by the ICLNs for the reduction in compliance
among HCAs is the highest.
After implementing the four programs, compliance increased to 83% in 2012
(n Z 1743, CI 81e85%) which is significant (p < 0.01) compared to
2009e2011. Alcohol hand rub consumption showed a similar trend in 2012,
increasing from 8.1L per 1000 patient-days in 2011 to 9.1L in 2012.
To overcome Hand Hygiene campaign fatigue it is important to be innovative
and adopting principles in management science. Results showed that
optimizing the collaboration of ICLN will bridge the implementation gaps
between the Infection Control Team and the frontline staff that significantly
improve hand hygiene compliance.KS 19
INFECTION CONTROL IN MULTI-DRUG RESISTANT ORGANISMS (MDROS)
Chun-Ming Lee, MD, PhD FCCP, DTCD(UK), DTM&H(UK). Chairman of
Infection Control Society of Taiwan, Mackay Memorial Hospital, Taipei,
TaiwanMultidrug-resistant organisms (MDROs),
including gram-positive coccus (GPC) such as
MRSA, VRE, VISA, VRSA and certain gram-
negative bacilli (GNB) such as ESBL, carbape-
nem-resistant enterobacteriaceae (CRE)
,CRPA and CRAB had important infection con-
trol implications. Although transmission of
MDROs ismost frequently documented in acute
care facilities, all healthcare settings affected
by the antimicrobial resistance rates are also
strongly correlatedwith hospital size, tertiary-
level care, and even facility type (e.g., LTCF).Emergence and transmission of antimicrobial-resistant microbes increased
lengths of stay, costs, patient mortality and legal problem also had been
associated with MDROs but the options for treating patients with these
infections are often extremely limited.
The various types of intervention used to control or eradicate MDROs may be
grouped into four major categories. These include diminishing healthcare
associated infections by different care bundles such as for CLABSI, UTI and
VAT, proper antibiotic stewardship policy (ASP), basic and advancedenvironment cleaning and hospital active surveillance. Using a combination
of interventions, MDROs in endemic, outbreak, and non-endemic settings
have been brought under control.
Despite the volume of literature, an appropriate set of evidence-based
control measures that can be universally applied in all healthcare settings
has not been definitively established. The approaches to prevent and
control of these pathogens need to be tailored to the specific needs of each
population and individual institution. Antimicrobial resistance and its
global spread, threatens the continued effectiveness of many medicines
used today to treat the sick, while at the same time it risks jeopardizing
important advances being made against major infectious killers. The
prevention and control of MDROs is a national priorityeone that requires
all healthcare facilities and all related government departments to assume
responsibility.
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WHONET e 25 (AND 50) YEARS ON
Thomas F. O’Brien, MD, John Stelling, MD, MPH. Brigham and Women’s
Hospital, WHO Collaborating Centre for Surveillance of Antimicrobial
Resistance, Boston, United StatesRoutine clinical microbiology laboratories
generate daily a detailed window into evolving
microbial populations worldwide. Our labora-
tory first createdmainframe-based routines for
the management of analysis of these data in
1964 for our own facility with a special focus on
antimicrobial susceptibility tests results and
the appearance and characterization of resis-
tant pathogens. In the 1970s, we initiated
national and international collaborations for
monitoring resistance. The introduction of per-
sonal computers in the 1980s permitted collab-
orating laboratories to enter and analyze their
own data for the first time, and our facility wasdesignated a WHO Collaborating Centre for Surveillance of Antimicrobial
Resistance in 1986. The name WHONET was given to the software package in
1989with the introduction of a software configurationmodulewhich permitted
the independent dissemination of our software worldwide. Since that time,
WHONET use has grown to support local, national, and global infection and
antimicrobial resistance surveillance activities in over 2,300 human, animal,
and food laboratories in over 110 countries worldwide. A current priority is
assisting the World Health Organization with implementation of the Global
Action Plan on Antimicrobial Resistance.
